Syndax Pharmaceuticals Future Growth
Future criteria checks 2/6
Syndax Pharmaceuticals is forecast to grow earnings and revenue by 24.4% and 43.9% per annum respectively. EPS is expected to grow by 26.3% per annum. Return on equity is forecast to be -46.3% in 3 years.
Key information
24.4%
Earnings growth rate
26.3%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | 43.9% |
| Future return on equity | -46.3% |
| Analyst coverage | Good |
| Last updated | 21 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 248 | -237 | -173 | -166 | 12 |
| 12/31/2025 | 99 | -333 | -262 | -271 | 13 |
| 12/31/2024 | 149 | -240 | -296 | -207 | 13 |
| 9/30/2024 | 16 | -297 | -259 | -259 | N/A |
| 6/30/2024 | 4 | -264 | -241 | -241 | N/A |
| 3/31/2024 | N/A | -241 | -205 | -205 | N/A |
| 12/31/2023 | N/A | -209 | -161 | -161 | N/A |
| 9/30/2023 | N/A | -176 | -142 | -142 | N/A |
| 6/30/2023 | N/A | -160 | -126 | -126 | N/A |
| 3/31/2023 | N/A | -153 | -131 | -131 | N/A |
| 12/31/2022 | N/A | -149 | -134 | -134 | N/A |
| 9/30/2022 | 127 | -14 | -10 | -10 | N/A |
| 6/30/2022 | 139 | 1 | -7 | -6 | N/A |
| 3/31/2022 | 139 | 15 | 10 | 10 | N/A |
| 12/31/2021 | 140 | 25 | 29 | 29 | N/A |
| 9/30/2021 | 14 | -92 | -87 | -87 | N/A |
| 6/30/2021 | 2 | -91 | -81 | -81 | N/A |
| 3/31/2021 | 2 | -86 | -78 | -78 | N/A |
| 12/31/2020 | 2 | -77 | -71 | -71 | N/A |
| 9/30/2020 | 2 | -71 | -68 | -68 | N/A |
| 6/30/2020 | 2 | -63 | -59 | -59 | N/A |
| 3/31/2020 | 2 | -61 | -50 | -50 | N/A |
| 12/31/2019 | 2 | -56 | -51 | -51 | N/A |
| 9/30/2019 | 2 | -61 | -53 | -53 | N/A |
| 6/30/2019 | 2 | -65 | -63 | -63 | N/A |
| 3/31/2019 | 2 | -69 | -66 | -65 | N/A |
| 12/31/2018 | 2 | -74 | -69 | -69 | N/A |
| 9/30/2018 | 2 | -74 | -66 | -66 | N/A |
| 6/30/2018 | 2 | -72 | N/A | -58 | N/A |
| 3/31/2018 | 2 | -67 | N/A | -55 | N/A |
| 12/31/2017 | 2 | -61 | N/A | -47 | N/A |
| 9/30/2017 | 1 | -53 | N/A | -45 | N/A |
| 6/30/2017 | 1 | -52 | N/A | -46 | N/A |
| 3/31/2017 | 1 | -47 | N/A | -41 | N/A |
| 12/31/2016 | 1 | -47 | N/A | -35 | N/A |
| 9/30/2016 | 1 | -45 | N/A | -29 | N/A |
| 6/30/2016 | 1 | -87 | N/A | -23 | N/A |
| 3/31/2016 | 1 | -105 | N/A | -20 | N/A |
| 12/31/2015 | 1 | -104 | N/A | -2 | N/A |
| 9/30/2015 | 0 | -100 | N/A | -2 | N/A |
| 6/30/2015 | 0 | -53 | N/A | 1 | N/A |
| 3/31/2015 | N/A | -33 | N/A | 1 | N/A |
| 12/31/2014 | N/A | -26 | N/A | -14 | N/A |
| 9/30/2014 | N/A | -31 | N/A | -14 | N/A |
| 6/30/2014 | N/A | -72 | N/A | -13 | N/A |
| 3/31/2014 | N/A | -67 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1T3 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1T3 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1T3 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1T3's revenue (43.9% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 1T3's revenue (43.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1T3 is forecast to be unprofitable in 3 years.